A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Open-Label Extension to the double-blind effectiveness and safety study R076477-SCH-305 to
evaluate long-term safety and tolerability in patients with schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.